Literature DB >> 29703652

Looking back and moving forward: On the application of proportional shortfall in healthcare priority setting in the Netherlands.

V T Reckers-Droog1, N J A van Exel2, W B F Brouwer3.   

Abstract

The increasing demand for healthcare and the resulting pressure on available budgets render priority setting inevitable. If societies aim to improve health and distribute health(care) fairly, equity-efficiency trade-offs are necessary. In the Netherlands, proportional shortfall (PS) was introduced to quantify necessity of care, allowing a direct equity-efficiency trade-off. This study describes the history and application of PS in the Netherlands and examines the theoretical and empirical support for PS as well as its current role in healthcare decision making. We reviewed the international literature on PS from 2001 onwards, along with publicly accessible meeting reports from the Dutch appraisal committee, Adviescommissie Pakket (ACP), from 2013 to 2016. Our results indicate that there is support for the decision model in which necessity is quantified and incremental cost-effectiveness ratios are evaluated against associated monetary reference values. The model enables a uniform framework for priority setting across all healthcare sectors. Although consensus about the application of PS has not yet been reached and alternative ways to quantify necessity were found in ACP reports, PS has increasingly been applied in decision making since 2015. However, empirical support for PS is limited and it may insufficiently reflect societal preferences regarding age and reducing lifetime-health inequalities. Hence, further investigation into refining PS-or exploration of another approach-appears warranted for operationalising the equity-efficiency trade-off.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Decision making; Equity; Priority setting; Proportional shortfall; Resource allocation; Social value

Mesh:

Year:  2018        PMID: 29703652     DOI: 10.1016/j.healthpol.2018.04.001

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  13 in total

1.  When is it too expensive? Cost-effectiveness thresholds and health care decision-making.

Authors:  Werner Brouwer; Pieter van Baal; Job van Exel; Matthijs Versteegh
Journal:  Eur J Health Econ       Date:  2019-03

2.  Who should receive treatment? An empirical enquiry into the relationship between societal views and preferences concerning healthcare priority setting.

Authors:  Vivian Reckers-Droog; Job van Exel; Werner Brouwer
Journal:  PLoS One       Date:  2018-06-27       Impact factor: 3.240

3.  Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.

Authors:  Linda M de Vries; Pieter H M van Baal; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

4.  The marginal benefits of healthcare spending in the Netherlands: Estimating cost-effectiveness thresholds using a translog production function.

Authors:  Niek Stadhouders; Xander Koolman; Christel van Dijk; Patrick Jeurissen; Eddy Adang
Journal:  Health Econ       Date:  2019-08-30       Impact factor: 3.046

5.  Severity-Adjusted Probability of Being Cost Effective.

Authors:  Matthijs M Versteegh; Isaac Corro Ramos; Nasuh C Buyukkaramikli; Amir Ansaripour; Vivian T Reckers-Droog; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2019-09       Impact factor: 4.981

6.  Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco-economic assessment.

Authors:  Carin A Uyl-de Groot; Rachel Ramsden; Dawn Lee; Janneke Boersma; Sonja Zweegman; Sujith Dhanasiri
Journal:  Eur J Haematol       Date:  2020-09-12       Impact factor: 2.997

7.  The impact of early phase price agreements on prices of orphan drugs.

Authors:  Mark Nuijten; Philippe Van Wilder
Journal:  BMC Health Serv Res       Date:  2021-03-12       Impact factor: 2.655

8.  Surgical treatment is not cost-effective compared to nonoperative treatment for displaced distal radius fractures in patients 65 years and over.

Authors:  Sondre Hassellund; Zinajda Zolic-Karlsson; John Håkon Williksen; Torstein Husby; Jan Erik Madsen; Frede Frihagen
Journal:  Bone Jt Open       Date:  2021-12

9.  Health economic evaluation of gene replacement therapies: methodological issues and recommendations.

Authors:  Samuel Aballéa; Katia Thokagevistk; Rimma Velikanova; Steven Simoens; Lieven Annemans; Fernando Antonanzas; Pascal Auquier; Clément François; Frank-Ulrich Fricke; Daniel Malone; Aurélie Millier; Ulf Persson; Stavros Petrou; Omar Dabbous; Maarten Postma; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2020-10-11

Review 10.  Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy.

Authors:  Tanja Fens; Eugène P van Puijenbroek; Maarten J Postma
Journal:  Front Med Technol       Date:  2021-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.